Non-Small-Cell Lung Cancer: Practical Guidance for a Rapidly Evolving Treatment Paradigm

Download All
Review the latest data and expert guidance on managing patients with NSCLC. This comprehensive program features clinical commentaries, a downloadable patient communication resource, updates to the online, interactive treatment decision support tools, and a text-based module along with downloadable slides.
Matthew Gubens, MD, MS
Stephen V. Liu, MD
Joel W. Neal, MD, PhD
H. Jack West, MD

ClinicalThought

How do you treat patients with advanced NSCLC in the era of immunotherapy? In this commentary, Dr. Gubens discusses the latest data on frontline combination regimens using immunotherapy for the treatment of advanced NSCLC.

Matthew Gubens, MD, MS Released: December 30, 2019

How do you manage patients with advanced squamous NSCLC in the era of immunotherapy? In this commentary, H. Jack West, MD, discusses the latest treatment options for advanced squamous NSCLC involving immune checkpoint inhibitors.

H. Jack West, MD Released: February 24, 2020

To benefit from targeted therapies for patients with advanced NSCLC, it is imperative that clinicians use biomarker testing to identify potential actionable gene aberrations. In this commentary, Joel Neal, MD, PhD, discusses his approach to this dynamic aspect of clinical care.

Joel W. Neal, MD, PhD Released: May 11, 2020

The combination of nivolumab and ipilimumab, with or without chemotherapy, is now approved for advanced NSCLC. Read my thoughts on the rationale for these approvals and how to integrate these regimens into clinical practice.

Stephen V. Liu, MD Released: July 6, 2020
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Grace Logo
Supported by educational grants from
Bristol-Myers Squibb
Celgene Corporation
Loxo Oncology, Inc. a wholly owned subsidiary of Eli Lilly and Company

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue